Indonesia has approved Sinovac BioTech’s COVID-19 vaccine for use in the elderly after receiving clinical trial results from China and Brazil.
Indonesia has suffered more than 31,000 deaths from COVID-19 and aims to vaccinate more than 180 million people, or roughly two-thirds of its population of 270 million, within a year.
According to Penny Lukito, Head of Indonesia’s Food and Drug RegulatorPenny Lukito, Head of Indonesia’s Food and Drug Regulator, the clinical trials showed no reports of serious side effects on the use of the vaccine. The first and second phase of clinical trials of the shot in China that involved 400 elderly people showed good results of the increased amount of antibodies.
In a letter, the Food and Drug Agency (BPOM) had authorized the use of Sinovac’s CoronaVac for the elderly “taking into account the emergency situation of the COVID-19 pandemic and the limited information on the benefits and safety of that vaccine.”